[Skip to Content]
[Skip to Content Landing]
Clinical Observation
September 28, 1998

Ischemic Colitis and Sumatriptan Use

Author Affiliations

From the Divisions of Neuropharmacologic Drug Products (Dr Knudsen) and Pharmacovigilance and Epidemiology, Office of Epidemiology and Biostatistics (Mss Friedman and Chen), Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Md; and the Department of Internal Medicine, Division of Gastroenterology, Cedars-Sinai Medical Center–UCLA School of Medicine, Los Angeles, Calif (Dr Goldwasser).

Arch Intern Med. 1998;158(17):1946-1948. doi:10.1001/archinte.158.17.1946

Sumatriptan succinate, a serotonin-l (5-hydroxytryptamine-1) receptor agonist, is an antimigraine drug that is reported to act by selectively constricting intracranial arteries. Recently, vasopressor responses that are distinct from the cranial circulation have been demonstrated to occur in the systemic, pulmonary, and coronary circulations. Cases have been published of coronary vasospasm, myocardial ischemia, and myocardial infarction occurring after sumatriptan use. We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with sumatriptan.